{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-037501","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.537743+00:00","generated_at":"2026-05-15T08:13:53.206110+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Oncology reports early LYMPHIR launch traction; 83% of target accounts in formulary review","bullets":["83% of target accounts have added or are actively progressing LYMPHIR through formulary review.","Market access covering ~80% of covered lives via ~135 health plans; no reimbursement denials reported.","Initial accounts placing repeat orders; sequential growth in orders since launch.","Investigator-led studies: LYMPHIR prior to CAR-T in DLBCL (U Minnesota) and combo with pembrolizumab in solid tumors (UPMC).","Field team onboarding underway; international expansion with distribution agreements in Europe/Middle East."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-037501","json":"https://secwatch.observer/filing/0001213900-26-037501.json","markdown":"https://secwatch.observer/filing/0001213900-26-037501.md","text":"https://secwatch.observer/filing/0001213900-26-037501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026037501/0001213900-26-037501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026037501/ea0284321-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:13:53.206110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}